Annah S Rolig

13PUBLICATIONS

57CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTissue engineeringInnate immunity

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 17, 2026

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

|Apr 29, 2026

YB-1 inhibition suppresses osteosarcoma growth and reverses tumor immunosuppression.

|May 22, 2025

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.

|Apr 09, 2025

The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming.

Annah S Rolig, Xiyu Peng, Elizabeth R Sturgill

|May 01, 2023

Characterization of murine lymphocyte activation and exhaustion markers by a 14-color flow cytometry panel.

Daniel C Rose, Annah S Rolig, William L Redmond

|Apr 21, 2022

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8<sup>+</sup> T cell cytotoxicity over BEMPEG+RT.

Annah S Rolig, Daniel C Rose, Grace Helen McGee

Pageof 3

Frequent Collaborators

William L Redmond

Nisha Holay

Emily Goers Sweeney

Karen Guillemin

Mohammad Farhad Amani

1 joint publications

Matthew G Vander Heiden

1 joint publications

Venkatesh Rajamanickam

1 joint publications

Mia Han

1 joint publications

Bianca Nguyen

1 joint publications

Jack Y Lee

Frequent Collaborators

William L Redmond

Nisha Holay

Emily Goers Sweeney

Karen Guillemin